Litigation Details for In Re Copaxone 40 MG Consolidated Cases (D. Del. 2014)

« Back to Dashboard

In Re Copaxone 40 MG Consolidated Cases (D. Del. 2014)

Docket		Date Filed	2014-09-10
Court	District Court, D. Delaware	Date Terminated	2017-01-31
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To
Parties	MYLAN INC.
Patents	6,468,967; 6,852,689; 8,232,250; 8,399,413; 8,552,025; 8,642,025; 8,969,302; 9,155,776; 9,555,023
Attorneys	Brandon M. White
Firms	Richards, Layton & Finger, PA
Link to Docket	External link to docket

Details for In Re Copaxone 40 MG Consolidated Cases (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-10				External link to document

In re Copaxone 40 MG Consolidated Cases, 1:14-cv-01171: Litigation Summary and Patent Analysis

Last updated: September 29, 2026

In re Copaxone 40 MG Consolidated Cases involved Teva Pharmaceuticals USA Inc.'s patent infringement claims against generic-drug companies seeking FDA approval to market 40-mg/mL glatiramer acetate injection. The lead case was filed in the U.S. District Court for the District of Delaware as C.A. No. 1:14-cv-01171. The litigation centered on Teva's patents covering the three-times-weekly Copaxone dosing regimen and related pharmaceutical compositions.

The principal commercial issue was whether generic manufacturers could launch 40-mg glatiramer acetate before expiration of Teva's Orange Book-listed patents. The litigation produced district-court and Federal Circuit decisions addressing claim construction, infringement, obviousness, written-description issues, and the scope of Teva's protection for the 40-mg regimen.

What was In re Copaxone 40 MG Consolidated Cases?

The proceeding consolidated patent cases arising from Abbreviated New Drug Applications, or ANDAs, for generic versions of Copaxone 40 mg/mL. Teva alleged that the ANDA filings constituted artificial acts of infringement under 35 U.S.C. § 271(e)(2).

Copaxone contains glatiramer acetate, a complex mixture of synthetic polypeptides approved for relapsing forms of multiple sclerosis. Teva marketed:

• Copaxone 20 mg/mL for once-daily injection.
• Copaxone 40 mg/mL for injection three times weekly, with at least one day between doses.

The 40-mg product reduced injection frequency while delivering twice the nominal dose per injection. Teva sought to prevent generic approval or launch by asserting patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.

Lead docket and court

Item	Detail
Lead case	In re Copaxone 40 MG Consolidated Cases
Lead docket	C.A. No. 1:14-cv-01171
Court	U.S. District Court for the District of Delaware
Judge	Richard G. Andrews
Plaintiff	Teva Pharmaceuticals USA Inc. and affiliated Teva entities
Product	Copaxone 40 mg/mL injection
Active ingredient	Glatiramer acetate
Legal pathway	ANDA patent litigation under the Hatch-Waxman Act
Core dispute	Whether generic 40-mg glatiramer acetate products infringed Teva's dosing and composition patents

Which patents protected Copaxone 40 mg?

The principal patent at issue was U.S. Patent No. 8,232,250, generally referred to as the '250 patent. The patent covered methods of treating multiple sclerosis using 40 mg of glatiramer acetate administered three times per week.

Teva also asserted U.S. Patent No. 8,399,413, referred to as the '413 patent, in related Copaxone litigation. The asserted patents were directed primarily to the 40-mg dosing regimen and associated pharmaceutical compositions rather than to a conventional small-molecule active ingredient.

Patent	General subject matter	Litigation relevance
U.S. Patent No. 8,232,250	Treatment of multiple sclerosis with 40 mg glatiramer acetate three times weekly	Principal patent in the 40-mg consolidated litigation
U.S. Patent No. 8,399,413	Related Copaxone 40-mg treatment and composition claims	Asserted in related proceedings and considered with the broader Copaxone patent estate
Other Teva Copaxone patents	Formulation, process, and treatment claims	Potentially relevant to separate ANDA cases and later generic-entry disputes

The '250 patent was commercially important because it did not merely claim glatiramer acetate as an active ingredient. It claimed a specific dosing schedule that differentiated Copaxone 40 mg from the older 20-mg daily product.

What were the main legal issues in the Copaxone litigation?

The core issues were claim construction, infringement, obviousness, written description, and whether the ANDA products would practice the claimed three-times-weekly regimen.

Claim construction

The court examined terms defining:

• The 40-mg amount of glatiramer acetate.
• Administration three times per week.
• The requirement for at least one day between injections.
• Treatment of a patient with multiple sclerosis.
• Pharmaceutical composition characteristics.

The dosing language was central. Generic applicants argued that their proposed labels and products did not necessarily require the exact claimed regimen. Teva argued that the ANDA submissions and proposed labeling directed physicians and patients to use the claimed schedule.

Infringement

Under 35 U.S.C. § 271(e)(2), Teva did not need to wait for commercial sales. The filing of an ANDA with a Paragraph IV certification created the statutory basis for the patent suit.

The infringement analysis focused on whether the generic products, as described in their ANDAs and proposed labeling, would be used in a manner that met the asserted claim limitations. The court also considered induced infringement principles because the proposed labeling could encourage the claimed method of treatment.

Obviousness

The generic defendants challenged the asserted claims under 35 U.S.C. § 103. Their arguments relied on earlier glatiramer acetate treatment information, the 20-mg daily regimen, and the possibility that a higher dose administered less frequently would have been an obvious modification.

Teva relied on the absence of a clear reason to select the claimed 40-mg, three-times-weekly schedule and on evidence that the regimen produced clinically meaningful benefits, including reduced injection frequency without loss of therapeutic efficacy.

The Federal Circuit's treatment of the '250 patent confirmed that the obviousness analysis required more than identifying the individual elements in the prior art. The relevant question was whether a skilled person would have had a reason to combine the prior-art teachings with a reasonable expectation of success.

Written description and enablement

The defendants also challenged whether Teva's patent disclosure adequately supported the full scope of the claimed regimen. The written-description dispute concerned whether the specification demonstrated possession of the specific 40-mg, three-times-weekly treatment method at the relevant filing date.

For a dosing patent, written-description risk can be substantial when the specification describes a broad therapeutic concept but the claims later identify a narrower dose and schedule. The Copaxone decisions treated the disclosure, clinical evidence, and development history as relevant to whether Teva possessed the claimed invention.

What was the outcome of the Copaxone 40 mg patent litigation?

The Delaware litigation resulted in rulings favorable to Teva on the enforceability and infringement of the principal 40-mg patent claims. The district court's decision was reviewed by the U.S. Court of Appeals for the Federal Circuit in Teva Pharmaceuticals USA Inc. v. Sandoz Inc.

The Federal Circuit addressed the validity and infringement issues involving the '250 patent and did not eliminate Teva's principal patent barrier to immediate generic entry. The appellate decision reinforced the importance of the specific dosing regimen and rejected the generic challenger's effort to invalidate the claims based on the cited prior art. (Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 789 F.3d 1335 (Fed. Cir. 2015); Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 809 F.3d 1344 (Fed. Cir. 2016).)

The litigation did not create permanent market exclusivity. Generic glatiramer acetate products later entered the U.S. market through FDA approvals, settlements, or the expiration and narrowing of relevant patent barriers.

Which companies challenged Teva's Copaxone patents?

The consolidated and related cases involved multiple ANDA applicants. The best-known litigants included Sandoz and Mylan, with additional generic manufacturers participating in related Copaxone patent proceedings.

Company	Role in the litigation
Sandoz Inc.	ANDA applicant and principal Federal Circuit litigant
Mylan Pharmaceuticals Inc.	Generic applicant in related Copaxone litigation
Natco Pharma Ltd.	Manufacturing and generic-product participant in related proceedings
Other ANDA applicants	Defendants in separate or consolidated cases depending on the asserted product and patent

The procedural posture varied by defendant. Some applicants litigated through trial and appeal. Others resolved claims through settlement agreements that established delayed launch dates or other market-entry terms.

Were there Paragraph IV challenges to Copaxone 40 mg?

Yes. The generic applicants filed Paragraph IV certifications asserting that Teva's patents were invalid, unenforceable, or not infringed. Teva responded with Hatch-Waxman infringement suits.

A Paragraph IV certification is commercially significant because it can trigger a 30-month FDA approval stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions. The stay delays final FDA approval while the patent case proceeds, but it does not itself determine the ultimate launch date. The date can be modified by court judgment, settlement, patent expiration, or other regulatory events.

The litigation illustrates the commercial value of method-of-use patents. A generic company can often seek approval for a product with a carve-out from patented use. That approach becomes more difficult where the patented dosing regimen is the principal or only commercially relevant indication and the proposed label encourages the patented use.

What was the Orange Book status of Copaxone 40 mg?

Teva listed patents for Copaxone in the Orange Book, including patents directed to the 40-mg, three-times-weekly regimen. Orange Book listing gave Teva a statutory basis to contest ANDA Paragraph IV certifications and obtain the potential 30-month stay.

Orange Book status should be evaluated patent by patent. Listing does not establish validity or infringement. It indicates that the NDA holder identified the patent as claiming the approved drug, a method of using the drug, or an approved-use feature recognized under FDA listing rules.

For Copaxone 40 mg, the commercial value of the listings depended on:

1. Whether the patent claims covered the proposed generic label.
2. Whether the patent survived validity challenges.
3. Whether the generic applicant could obtain approval with a skinny label.
4. Whether the applicant could launch after settlement or court judgment.
5. Whether additional formulation or manufacturing patents created residual risk.

When did Copaxone 40 mg lose exclusivity?

Copaxone 40 mg lost practical exclusivity through a combination of patent litigation, settlements, FDA approvals, and generic launches rather than through a single event.

The '250 patent had an expiration date in the early 2030s based on its patent term, but the commercial exclusivity period for Copaxone 40 mg ended earlier because generic companies obtained approval and entered the market under negotiated or otherwise authorized conditions. Patent expiration is therefore not the same as the date of first generic competition.

Exclusivity component	Commercial effect
FDA approval of Copaxone 40 mg	Established the branded product and its approved dosing regimen
Orange Book listings	Enabled Hatch-Waxman patent enforcement
Paragraph IV litigation	Delayed or accelerated generic approval depending on outcome
Settlement agreements	Could authorize entry before patent expiration
FDA approval of generics	Allowed approved competition subject to patent and settlement constraints
Patent expiration	Removed remaining enforceable patent barriers

Copaxone also benefited from regulatory exclusivity associated with its original approvals, but the later commercial dispute was driven primarily by patent protection and generic-entry arrangements.

What formulations were protected by Copaxone patents?

The principal '250 patent dispute was a method-of-use and dosing dispute rather than a basic formulation patent case. The commercial product was a sterile injectable solution containing glatiramer acetate at a 40-mg/mL concentration.

Potential formulation and manufacturing issues included:

• Concentration of glatiramer acetate.
• Injectable solution composition.
• Sterility and preservative characteristics.
• Container and delivery system.
• Manufacturing controls for a complex polymer mixture.
• Product sameness and analytical characterization.

Glatiramer acetate is not a single, well-defined small molecule. It is a heterogeneous mixture of synthetic polypeptides. That characteristic can create regulatory and technical barriers for generic manufacturers, even when the legal patent barrier is reduced.

How strong was Teva's Copaxone patent estate?

Teva's Copaxone patent estate was strongest where it covered the commercially differentiated 40-mg regimen and where the proposed generic labeling directly tracked the patented use.

Strengths

• The '250 patent targeted the commercially important three-times-weekly regimen.
• The claim set addressed a specific dose and dosing frequency.
• The patent supported a direct Hatch-Waxman infringement theory.
• Generic applicants faced difficulty avoiding the claimed regimen while seeking approval for the same commercial use.
• The case generated favorable district-court and Federal Circuit treatment for the principal patent.

Weaknesses

• Method-of-use claims can be vulnerable to skinny-label strategies.
• The asserted claims faced obviousness and written-description challenges.
• A successful settlement could permit generic entry before patent expiration.
• Product and process patents had to be assessed separately from the dosing patent.
• Generic competition could arise even while later-expiring patents remained on the books.

Overall, Teva's patent position was strong against a full-label generic seeking approval for the 40-mg three-times-weekly indication. It was less absolute against a generic using a label carve-out, relying on noninfringing instructions, or entering under a settlement.

What litigation and settlement risks affected generic launch?

The principal risks for a generic applicant were:

1. A finding that the ANDA filing infringed the '250 patent.
2. Loss on invalidity defenses.
3. A prolonged 30-month stay.
4. An injunction or judgment delaying commercial launch.
5. Exposure to damages if the product launched before resolution.
6. Regulatory difficulty obtaining approval for a label that omitted the patented regimen.
7. Manufacturing and product-sameness challenges associated with glatiramer acetate.

Settlement agreements could reduce those risks by setting a defined entry date. The economic value of a settlement depended on the agreed launch date, the number of competing entrants, the scope of any license, and whether the agreement included restrictions beyond the relevant patents.

What was the business impact of the litigation?

Copaxone was one of Teva's largest products. The 40-mg formulation was commercially important because it shifted patients from daily injections to three injections per week and helped Teva manage erosion of the older 20-mg product.

Generic entry threatened:

• U.S. Copaxone revenue.
• Net pricing and rebates.
• Patient retention.
• Teva's multiple sclerosis franchise.
• The value of Teva's remaining patent and regulatory rights.

The litigation delayed unrestricted generic competition but did not prevent eventual market erosion. Once approved generic glatiramer acetate products became available, the commercial assessment turned on substitution rates, payer formularies, physician prescribing, product tolerability, and the number of approved competitors.

Key Takeaways

• In re Copaxone 40 MG Consolidated Cases, C.A. No. 1:14-cv-01171, was a Delaware Hatch-Waxman litigation involving Teva's Copaxone 40 mg/mL product.
• The principal patent was U.S. Patent No. 8,232,250, covering 40 mg of glatiramer acetate administered three times weekly.
• Sandoz and other generic applicants challenged the patents through Paragraph IV certifications.
• The litigation addressed claim construction, infringement, obviousness, written description, and the effect of proposed generic labeling.
• Teva obtained favorable rulings on the principal 40-mg patent in the district court and Federal Circuit proceedings.
• The litigation delayed unrestricted generic entry but did not preserve Copaxone exclusivity through the full patent term.
• Formulation, manufacturing, and product-sameness issues remained relevant because glatiramer acetate is a complex polypeptide mixture.
• Generic-entry timing depended on litigation outcomes, settlement terms, FDA approvals, patent listings, and label strategy.

FAQs About In re Copaxone 40 MG Consolidated Cases

What is the case number for the Copaxone 40 mg litigation?

The lead Delaware docket is C.A. No. 1:14-cv-01171, styled In re Copaxone 40 MG Consolidated Cases.

What drug was at issue in the case?

The case involved Copaxone 40 mg/mL injection, whose active ingredient is glatiramer acetate, an injectable treatment for relapsing forms of multiple sclerosis.

Which Copaxone patent was most important?

U.S. Patent No. 8,232,250 was the principal patent because it covered the 40-mg, three-times-weekly treatment regimen.

Did the Copaxone litigation involve biosimilars?

No. The case involved ANDA-based generic applicants, not biosimilar applicants under the Biologics Price Competition and Innovation Act. Glatiramer acetate is regulated as a drug product for this purpose.

Why was the 40-mg formulation commercially important?

The 40-mg product allowed administration three times per week instead of the once-daily schedule associated with Copaxone 20 mg, giving Teva a differentiated product during the multiple sclerosis market's transition toward reduced injection frequency.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
2. U.S. Food and Drug Administration. (n.d.). Copaxone prescribing information. FDA.
3. Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 789 F.3d 1335 (Fed. Cir. 2015).
4. Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 809 F.3d 1344 (Fed. Cir. 2016).
5. U.S. District Court for the District of Delaware. (2014-2017). In re Copaxone 40 MG Consolidated Cases, C.A. No. 1:14-cv-01171.
6. U.S. Patent No. 8,232,250. (2012). Glatiramer acetate treatment methods. U.S. Patent and Trademark Office.
7. U.S. Patent No. 8,399,413. (2013). Glatiramer acetate compositions and methods. U.S. Patent and Trademark Office.